Importance There is tremendous interest in using immunotherapy to treat breast cancer, as
evidenced by the more than 290 clinical trials ongoing at the time of this narrative review …

Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-
ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable …

Historically, breast cancer tumors have been considered immunologically quiescent, with
the majority of tumors demonstrating low lymphocyte infiltration, low mutational burden, and …

Background HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal
antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression …

Background Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the
extracellular domain of transforming growth factor (TGF)-βRII (a TGF-β 'trap') fused to a …

Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …

Importance Cytokine storm due to COVID-19 can cause high morbidity and mortality and
may be more common in patients with cancer treated with immunotherapy (IO) due to …

Therapeutic cancer vaccines have gained significant popularity in recent years as new
approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines …

Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are
associated with modest response rates as monotherapy in metastatic breast cancer, but are …

Purpose: BN-CV301 is a poxviral-based vaccine comprised of recombinant (rec.) modified
vaccinia Ankara (MVA-BN-CV301; prime) and rec. fowlpox (FPV-CV301; boost). Like its …